基因治疗:内耳递送途径
本文综述内耳基因治疗的递送途径,指出圆窗膜注射是动物模型中最常用的方法,但存在载体分布受限、可能形成从底转到顶转梯度的缺点。鼓阶造孔或半规管开窗等通气操作以及鞘内甚至宫内注射等替代途径正在探索中,不同遗传性耳聋的递送策略需持续评估。
要点
- 圆窗膜注射在动物模型中可使耳蜗毛细胞转导,但载体分布有限。
- 鼓阶造孔或半规管开窗等通气操作可能改善载体分布。
- 不同遗传性耳聋的基因递送策略可能不同,需个体化评估。
核心结论
- 内耳基因递送途径快速发展,圆窗膜注射虽常用但存在分布局限,多种替代途径正在探索。
研究设计与样本
- 综述,总结基因治疗内耳递送途径的转化与临床研究进展。
主要发现
- 动物模型中多数基因递送通过圆窗膜注射完成,在耳蜗毛细胞转导中结果良好。
- 圆窗膜注射的潜在缺点包括载体分布有限,可能导致从底转到顶转的梯度。
- 鼓阶造孔或半规管开窗等通气操作已被探索以减轻上述局限。
- 鞘内甚至宫内注射已被研究作为替代途径。
- CRISPR/Cas编辑工具的最新成功可能影响基因治疗类型的选择。
临床怎么用
- 临床选择内耳基因递送途径时需权衡圆窗膜注射的分布局限与通气操作等替代途径的潜在获益。
- 应根据听力损失的遗传病因个体化评估基因递送策略。
局限性
- 综述未报告具体样本量、阈值或疗效数据,多数证据来自动物模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene delivery and the various routes of administration used to deliver viral vectors constitute a rapidly evolving field, with recent success in restoring hearing in children with OTOF variants in ongoing clinical otoferlin trials. With the rise of gene therapy for major hereditary hearing disorders, both syndromic and nonsyndromic, there has been parallel progress in the development of new delivery methods. Advances in intratympanic injection of antibiotics and corticosteroids, along with nearly half a century of experience in cochlear implantation surgery, have enabled multiple local and systemic approaches to access the inner ear. Recent industry investment in gene therapy and delivery technologies has accelerated scientific progress, underscoring the need for continuous evaluation of the most suitable gene delivery strategies for different causes of hearing loss. Although most gene delivery in animal models has been performed via round window membrane injection, yielding promising results in cochlear hair cell transduction, potential drawbacks remain for clinical translation-particularly limited vector distribution, which may result in a basal-to-apical gradient. Venting procedures such as stapes footplate fenestration or canalostomy have been explored to mitigate these limitations, and recent intrathecal or even in utero injections have been investigated as alternative approaches. Hearing loss can be inherited in multiple ways, and patient treatment with gene delivery, or even the type of gene therapy itself, may vary with the recent success of CRISPR/Cas-based editing tools. Understanding the genetic etiology of inner ear disorders has facilitated the identification of therapeutic targets and innovative delivery approaches. This review summarizes the current understanding of delivery routes for gene therapy, highlighting their respective strengths and limitations as demonstrated in translational and clinical research to date. Furthermore, it examines advances in drug delivery and clinical applications in the context of emerging therapeutics, providing an integrated overview and perspective on the future direction of gene delivery strategies.
引用
- Yildiz E, Arnoldner C. Gene Therapy: Routes of Inner Ear Delivery. Ear Hear. 2026. PMID: 42868211. doi:10.1097/AUD.0000000000001771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。